Sufotidine is a long-acting competitive H2 receptor antagonist which was under development as an antiulcerant. It was planned to be a follow-up compound to ranitidine (Zantac). When taken in doses of 600 mg twice daily it induced virtually 24-hour gastric anacidity thus closely resembling the antisecretory effect of the proton pump inhibitor omeprazole. Its development was terminated based on the appearance of carcinoid tumors in long-term toxicity testing in rodents. References: Mela GS, Caputo E, Villa G, Savarino V, Zentilin P. Intragastric acidity and serum gastrin after sufotidine. Gut. 1990 Sep;31(9):1087-8. PubMed PMID: 1976577; PubMed Central PMCID: PMC1378679.

纯度：≥98%

CAS：80343-63-1